TINAGL1

Summary

TINAGL1 (tubulointerstitial nephritis antigen like 1, HGNC:19168) is a protein-coding gene on chromosome 1p35.2, encoding Tubulointerstitial nephritis antigen-like (Q9GZM7). May be implicated in the adrenocortical zonation and in mechanisms for repressing the CYP11B1 gene expression in adrenocortical cells.

The protein encoded by this gene is similar in sequence to tubulointerstitial nephritis antigen, a secreted glycoprotein that is recognized by antibodies in some types of immune-related tubulointerstitial nephritis. Three transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 64129 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 56 total
• MANE Select transcript: NM_022164

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19168
Approved symbol	TINAGL1
Name	tubulointerstitial nephritis antigen like 1
Location	1p35.2
Locus type	gene with protein product
Status	Approved
Aliases	P3ECSL, LIECG3, ARG1, TINAGRP
Ensembl gene	ENSG00000142910
Ensembl biotype	protein_coding
OMIM	616064
Entrez	64129

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 9 protein_coding, 8 protein_coding_CDS_not_defined

ENST00000271064, ENST00000457433, ENST00000461030, ENST00000463112, ENST00000466998, ENST00000468635, ENST00000478398, ENST00000480586, ENST00000481165, ENST00000498429, ENST00000537531, ENST00000861775, ENST00000861776, ENST00000861777, ENST00000861778, ENST00000861779, ENST00000964677

RefSeq mRNA: 3 — MANE Select: NM_022164 NM_001204414, NM_001204415, NM_022164

CCDS: CCDS343, CCDS55586, CCDS72745

Canonical transcript exons

ENST00000271064 — 12 exons

Exon	Start	End
ENSE00001303285	31577134	31577458
ENSE00001930233	31576515	31576595
ENSE00003462189	31586839	31587686
ENSE00003488018	31583149	31583241
ENSE00003500839	31585753	31585876
ENSE00003500934	31586710	31586755
ENSE00003602960	31584886	31585036
ENSE00003624313	31584678	31584801
ENSE00003626228	31585151	31585340
ENSE00003653039	31585440	31585485
ENSE00003690425	31579204	31579267
ENSE00003694138	31583461	31583575

Expression profiles

Bgee: expression breadth ubiquitous, 201 present calls, max score 99.34.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 35.7644 / max 1040.1499, expressed in 944 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
1922	26.9413	899
1923	8.1694	731
1921	0.3224	142
1926	0.1067	51
1925	0.1048	50
1928	0.0645	21
1927	0.0434	15
1924	0.0119	4

Top tissues by expression

264 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
metanephros cortex	UBERON:0010533	99.34	gold quality
right coronary artery	UBERON:0001625	99.30	gold quality
ascending aorta	UBERON:0001496	99.17	gold quality
thoracic aorta	UBERON:0001515	99.16	gold quality
popliteal artery	UBERON:0002250	99.04	gold quality
tibial artery	UBERON:0007610	99.04	gold quality
descending thoracic aorta	UBERON:0002345	99.01	gold quality
apex of heart	UBERON:0002098	99.00	gold quality
aorta	UBERON:0000947	98.99	gold quality
left coronary artery	UBERON:0001626	98.84	gold quality
right lobe of thyroid gland	UBERON:0001119	98.67	gold quality
left lobe of thyroid gland	UBERON:0001120	98.32	gold quality
omental fat pad	UBERON:0010414	98.27	gold quality
left uterine tube	UBERON:0001303	98.21	gold quality
body of uterus	UBERON:0009853	98.20	gold quality
peritoneum	UBERON:0002358	98.19	gold quality
endocervix	UBERON:0000458	97.81	gold quality
coronary artery	UBERON:0001621	97.63	gold quality
heart left ventricle	UBERON:0002084	97.61	gold quality
lower esophagus muscularis layer	UBERON:0035833	97.58	gold quality
right lung	UBERON:0002167	97.56	gold quality
lower esophagus	UBERON:0013473	97.54	gold quality
right atrium auricular region	UBERON:0006631	97.51	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	97.50	gold quality
mucosa of stomach	UBERON:0001199	97.43	gold quality
ectocervix	UBERON:0012249	97.37	gold quality
gall bladder	UBERON:0002110	97.32	gold quality
upper lobe of left lung	UBERON:0008952	97.23	gold quality
transverse colon	UBERON:0001157	97.22	gold quality
thyroid gland	UBERON:0002046	97.21	gold quality

Single-cell (SCXA)

Detected in 23 experiment(s), a significant marker in 22.

Experiment	Marker?	Max mean expression
E-MTAB-6701	yes	1303.46
E-MTAB-5061	yes	1251.73
E-GEOD-134144	yes	921.49
E-CURD-126	yes	773.46
E-HCAD-36	yes	662.22
E-MTAB-6108	yes	617.04
E-HCAD-10	yes	567.41
E-MTAB-7249	yes	211.77
E-GEOD-83139	yes	207.80
E-ENAD-27	yes	165.30
E-MTAB-10287	yes	66.86
E-MTAB-10553	yes	49.78
E-HCAD-11	yes	43.24
E-GEOD-135922	yes	38.30
E-HCAD-1	yes	36.22

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

28 targeting TINAGL1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-1296-3P	99.72	64.04	636
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-6507-5P	99.36	70.46	2524
HSA-MIR-10522-5P	99.26	68.50	2087
HSA-MIR-6799-5P	99.14	65.72	2093
HSA-MIR-939-3P	98.97	65.07	2347
HSA-MIR-6846-5P	98.81	65.86	1121
HSA-MIR-6848-5P	98.81	65.49	1126
HSA-MIR-6840-3P	98.68	65.95	1923
HSA-MIR-7977	98.65	66.18	2590
HSA-MIR-4664-5P	98.17	65.07	1020
HSA-MIR-4421	97.99	64.89	701
HSA-MIR-5699-3P	97.81	65.00	861
HSA-MIR-1285-3P	97.72	67.02	1932
HSA-MIR-1233-3P	96.81	65.44	573

Literature-anchored findings (GeneRIF, showing 6)

• Double immunofluorescence analysis showed that CTLA-2alpha was co-localized with cathepsin L, cathepsin C, and TINAGL1 in placenta. (PMID:25514977)
• TINAGL1 and B3GALNT1 are possible candidates for drug compounds that inhibit their gene expression (PMID:25521548)
• Results show that lower TINAGL1 expression correlates with advanced triple-negative breast cancer (TNBC) tumor stages, reduced disease-free survival (DFS) and distant metastasis-free survival. Consistent with higher risk of metastatic relapse in breast tumors with lower expression of TINAGL1, highly metastatic human breast cancer cell lines express lower TINAGL1 levels than weakly metastatic cells. (PMID:30612941)
• Tubulointerstitial nephritis antigen-like 1 is a novel matricellular protein that promotes gastric bacterial colonization and gastritis in the setting of Helicobacter pylori infection. (PMID:37336990)
• Tubulointerstitial nephritis antigen-like 1 from cancer-associated fibroblasts contribute to the progression of diffuse-type gastric cancers through the interaction with integrin beta1. (PMID:38355577)
• YTHDF1 facilitates esophageal cancer progression via augmenting m6A-dependent TINAGL1 translation. (PMID:39098703)

Cross-species orthologs

16 orthologs

Organism	Symbol	Gene ID
mus_musculus	Tinagl1	ENSMUSG00000028776
rattus_norvegicus	Tinagl1	ENSRNOG00000013179
caenorhabditis_elegans		WBGENE00000781
caenorhabditis_elegans		WBGENE00000782
caenorhabditis_elegans		WBGENE00000784
caenorhabditis_elegans		WBGENE00000785
caenorhabditis_elegans	cpz-1	WBGENE00000788
caenorhabditis_elegans		WBGENE00013072
caenorhabditis_elegans		WBGENE00013076
caenorhabditis_elegans		WBGENE00013764
caenorhabditis_elegans		WBGENE00016300
caenorhabditis_elegans		WBGENE00016306
caenorhabditis_elegans		WBGENE00019314
caenorhabditis_elegans		WBGENE00019986
caenorhabditis_elegans		WBGENE00022189
caenorhabditis_elegans		WBGENE00044760

Paralogs (12): CTSZ (ENSG00000101160), CTSH (ENSG00000103811), CTSC (ENSG00000109861), CTSL (ENSG00000135047), CTSV (ENSG00000136943), TINAG (ENSG00000137251), CTSK (ENSG00000143387), CTSS (ENSG00000163131), CTSB (ENSG00000164733), CTSW (ENSG00000172543), CTSF (ENSG00000174080), CTSO (ENSG00000256043)

Protein

Protein identifiers

Tubulointerstitial nephritis antigen-like — Q9GZM7 (reviewed: Q9GZM7)

Alternative names: Glucocorticoid-inducible protein 5, Oxidized LDL-responsive gene 2 protein, Tubulointerstitial nephritis antigen-related protein

All UniProt accessions (2): Q9GZM7, F6SDV2

UniProt curated annotations — full annotation on UniProt →

Function. May be implicated in the adrenocortical zonation and in mechanisms for repressing the CYP11B1 gene expression in adrenocortical cells. This is a non catalytic peptidase C1 family protein.

Subcellular location. Secreted.

Tissue specificity. Highly expressed in aorta, heart, placenta, kidney and a colorectal adenocarcinoma cell line. Moderately expressed in skeletal muscle, pancreas, lung, lymph nodes, adrenal gland, bone marrow and thyroid. Weakly expressed in colon, small intestine, ovary, spleen, testis and prostate. Predominantly found in vascular smooth muscle cells, but also in cardiac and skeletal muscle cells as well as kidney.

Post-translational modifications. Glycosylated.

Similarity. Belongs to the peptidase C1 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9GZM7-1	1	yes
Q9GZM7-2	2
Q9GZM7-3	3

RefSeq proteins (3): NP_001191343, NP_001191344, NP_071447* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000668	Peptidase_C1A_C	Domain
IPR001212	Somatomedin_B_dom	Domain
IPR013128	Peptidase_C1A	Family
IPR025660	Pept_his_AS	Active_site
IPR038765	Papain-like_cys_pep_sf	Homologous_superfamily

Pfam: PF00112

UniProt features (19 total): splice variant 6, disulfide bond 5, sequence conflict 2, glycosylation site 2, signal peptide 1, chain 1, sequence variant 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9GZM7-F1	86.54	0.69

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (5): 54–73, 71–85, 71–73, 77–84, 85–92

Glycosylation sites (2): 78, 161

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 510 (showing top): GSE45365_HEALTHY_VS_MCMV_INFECTION_CD8_TCELL_IFNAR_KO_DN, GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_DN, GOBP_REGULATION_OF_CELL_ACTIVATION, SHEPARD_BMYB_MORPHOLINO_UP, GOBP_REGULATION_OF_LEUKOCYTE_PROLIFERATION, AP1_01, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_NEGATIVE_REGULATION_OF_ADAPTIVE_IMMUNE_RESPONSE, MODULE_255, GOBP_RESPONSE_TO_PEPTIDE, GOCC_SECRETORY_GRANULE, GOBP_NEGATIVE_REGULATION_OF_LEUKOCYTE_PROLIFERATION, GOBP_REGULATION_OF_ADAPTIVE_IMMUNE_RESPONSE, GOBP_ALPHA_AMINO_ACID_METABOLIC_PROCESS, GOBP_NEGATIVE_REGULATION_OF_PRODUCTION_OF_MOLECULAR_MEDIATOR_OF_IMMUNE_RESPONSE

GO Biological Process (2): endosomal transport (GO:0016197), proteolysis (GO:0006508)

GO Molecular Function (4): extracellular matrix structural constituent (GO:0005201), laminin binding (GO:0043236), protein binding (GO:0005515), cysteine-type peptidase activity (GO:0008234)

GO Cellular Component (6): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), lysosome (GO:0005764), extracellular matrix (GO:0031012), extracellular exosome (GO:0070062), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
vesicle-mediated transport	1
intracellular transport	1
protein metabolic process	1
structural molecule activity	1
extracellular matrix	1
protein binding	1
extracellular matrix binding	1
binding	1
peptidase activity	1
lytic vacuole	1
external encapsulating structure	1
extracellular vesicle	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

658 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TINAGL1	SEC23A	Q15436	595
TINAGL1	GADD45GIP1	Q8TAE8	500
TINAGL1	TMEM184A	Q6ZMB5	467
TINAGL1	EGFR	P00533	461
TINAGL1	KAT5	Q92993	449
TINAGL1	PGLYRP1	O75594	439
TINAGL1	ZEB2	O60315	412
TINAGL1	SACK1B	Q5T0W9	406
TINAGL1	CFH	P08603	404
TINAGL1	TINAG	Q9UJW2	399
TINAGL1	PEF1	Q9UBV8	385
TINAGL1	C3	P01024	374
TINAGL1	IGFBP4	P22692	372
TINAGL1	TMEM61	Q8N0U2	367
TINAGL1	ZEB1	P37275	358

IntAct

86 interactions, top by confidence:

A	B	Type	Score
TINAGL1	TRIP13	psi-mi:“MI:0915”(physical association)	0.720
TRIP13	TINAGL1	psi-mi:“MI:0915”(physical association)	0.720
CAMKV	AP3B1	psi-mi:“MI:0914”(association)	0.640
TULP3	GGPS1	psi-mi:“MI:0914”(association)	0.640
KRTAP12-2	TINAGL1	psi-mi:“MI:0915”(physical association)	0.560
TINAGL1	KRTAP12-2	psi-mi:“MI:0915”(physical association)	0.560
PITX2	TINAGL1	psi-mi:“MI:0915”(physical association)	0.560
PROP1	TINAGL1	psi-mi:“MI:0915”(physical association)	0.560
BAG4	TINAGL1	psi-mi:“MI:0915”(physical association)	0.560
FBXO2	TMEM131L	psi-mi:“MI:0914”(association)	0.530
TULP3	HSPG2	psi-mi:“MI:0914”(association)	0.530
TINAGL1	L2	psi-mi:“MI:0407”(direct interaction)	0.440
TINAGL1	EP300	psi-mi:“MI:0915”(physical association)	0.370
LMO4	TINAGL1	psi-mi:“MI:0915”(physical association)	0.370
SMAD9	TINAGL1	psi-mi:“MI:0915”(physical association)	0.370
MDFI	TINAGL1	psi-mi:“MI:0915”(physical association)	0.370
TINAGL1	PRMT5	psi-mi:“MI:0914”(association)	0.350
CTSK	POTEF	psi-mi:“MI:0914”(association)	0.350
PI15		psi-mi:“MI:0914”(association)	0.350
PRG2	QSOX1	psi-mi:“MI:0914”(association)	0.350
FIGLA	TCF3	psi-mi:“MI:0914”(association)	0.350
AKIRIN2	HSPG2	psi-mi:“MI:0914”(association)	0.350
SULF2	IGKV2-29	psi-mi:“MI:0914”(association)	0.350
CDH5	ESYT2	psi-mi:“MI:2364”(proximity)	0.270
CDH5	MYO1C	psi-mi:“MI:2364”(proximity)	0.270
TINAGL1	TRIP13	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (50): TINAGL1 (Two-hybrid), TINAGL1 (Two-hybrid), KRTAP4-2 (Two-hybrid), KRTAP12-2 (Two-hybrid), KRTAP10-3 (Two-hybrid), NOTCH2NL (Two-hybrid), PRMT5 (Affinity Capture-MS), GNB2 (Affinity Capture-MS), CD59 (Affinity Capture-MS), RIOK1 (Affinity Capture-MS), HSPG2 (Affinity Capture-MS), LOXL2 (Affinity Capture-MS), TINAGL1 (Two-hybrid), HSPG2 (Affinity Capture-MS), RIOK1 (Affinity Capture-MS)

ESM2 similar proteins: A0A0D3QS98, A0A0D3QS99, A2A5I3, O19010, O19011, O42596, P01137, P04202, P04629, P07200, P09533, P16562, P17246, P18341, P35739, P50414, P54108, P54831, P57110, Q01974, Q38HS2, Q3KPV7, Q3UFB7, Q505J3, Q5R7Y0, Q5T4F7, Q60477, Q658N2, Q6UWX4, Q7T141, Q7TSQ1, Q80XH4, Q8BG58, Q91009, Q99JR5, Q9CXM0, Q9D2G9, Q9EQT5, Q9GZM7, Q9H3Y0

Diamond homologs: A0A0F7G352, A0E358, A1E295, F4HVZ1, G5EGP8, O46427, O60911, O97578, P00787, P05167, P05993, P07688, P07711, P07858, P09668, P0DO76, P10605, P19092, P25774, P25778, P25792, P25793, P25802, P25807, P32954, P36400, P43157, P43233, P43507, P43508, P43509, P43510, P49935, P53634, P81494, P83205, P90850, P92131, P92132, P92133

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

56 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	42
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2651 predictions. Top by Δscore:

Variant	Effect	Δscore
1:31583148:GC:G	acceptor_gain	1.0000
1:31583240:GG:G	donor_gain	1.0000
1:31583241:GG:G	donor_gain	1.0000
1:31583576:G:GG	donor_gain	1.0000
1:31584676:A:AG	acceptor_gain	1.0000
1:31584677:G:GA	acceptor_gain	1.0000
1:31584677:GAC:G	acceptor_gain	1.0000
1:31584677:GACA:G	acceptor_gain	1.0000
1:31584798:GCAG:G	donor_gain	1.0000
1:31584799:CAGGT:C	donor_loss	1.0000
1:31584800:AGGTA:A	donor_loss	1.0000
1:31584801:GGT:G	donor_loss	1.0000
1:31584802:G:GG	donor_gain	1.0000
1:31584803:T:A	donor_loss	1.0000
1:31584880:CACCA:C	acceptor_loss	1.0000
1:31584881:ACCAG:A	acceptor_loss	1.0000
1:31584882:CCAGC:C	acceptor_loss	1.0000
1:31584883:CAGC:C	acceptor_loss	1.0000
1:31584884:A:AG	acceptor_gain	1.0000
1:31584885:G:GG	acceptor_gain	1.0000
1:31584885:G:GT	acceptor_loss	1.0000
1:31584885:GCT:G	acceptor_gain	1.0000
1:31584885:GCTGT:G	acceptor_gain	1.0000
1:31585033:GAGG:G	donor_gain	1.0000
1:31585035:GG:G	donor_gain	1.0000
1:31585036:GG:G	donor_gain	1.0000
1:31585137:T:A	acceptor_gain	1.0000
1:31585140:T:A	acceptor_gain	1.0000
1:31585149:A:AG	acceptor_gain	1.0000
1:31585149:AG:A	acceptor_gain	1.0000

AlphaMissense

3058 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:31584901:G:C	R241P	0.999
1:31584785:G:C	W230C	0.998
1:31584785:G:T	W230C	0.998
1:31584963:T:A	C262S	0.998
1:31584964:G:A	C262Y	0.998
1:31584964:G:C	C262S	0.998
1:31586856:G:C	W427C	0.998
1:31586856:G:T	W427C	0.998
1:31583464:G:C	W157C	0.997
1:31583464:G:T	W157C	0.997
1:31584783:T:A	W230R	0.997
1:31584783:T:C	W230R	0.997
1:31584964:G:T	C262F	0.997
1:31585272:T:A	C327S	0.997
1:31585273:G:C	C327S	0.997
1:31585864:T:A	V402D	0.997
1:31586850:C:A	N425K	0.997
1:31586850:C:G	N425K	0.997
1:31586854:T:A	W427R	0.997
1:31586854:T:C	W427R	0.997
1:31577377:T:A	C77S	0.996
1:31577378:G:C	C77S	0.996
1:31579257:T:A	C122S	0.996
1:31579258:G:C	C122S	0.996
1:31583192:T:A	C140S	0.996
1:31583193:G:C	C140S	0.996
1:31583194:C:G	C140W	0.996
1:31583462:T:A	W157R	0.996
1:31583462:T:C	W157R	0.996
1:31584771:T:A	C226S	0.996

dbSNP variants (sampled 300 via entrez): RS1000060719 (1:31580423 G>A), RS1000906918 (1:31586206 G>A), RS1001187412 (1:31587085 G>A,T), RS1001241447 (1:31587310 C>A,G,T), RS1001454617 (1:31575652 C>G), RS1001555494 (1:31574860 T>C), RS1001570509 (1:31575377 C>T), RS1002067119 (1:31579762 G>A,T), RS1002072675 (1:31583197 G>A,C), RS1002506012 (1:31576013 C>T), RS1002968619 (1:31576368 T>A,C,G), RS1003064583 (1:31580247 C>G,T), RS1003460879 (1:31578018 C>T), RS1003577284 (1:31577722 C>T), RS1003684988 (1:31584260 C>T)

Disease associations

OMIM: gene MIM:616064 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST005316_437	Intelligence (MTAG)	2.000000e-09
GCST005316_440	Intelligence (MTAG)	9.000000e-09
GCST005951_36	Body mass index	9.000000e-10
GCST006186_9	Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)	2.000000e-07
GCST006193_8	Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)	8.000000e-06
GCST006195_95	Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)	8.000000e-10
GCST006269_693	General cognitive ability	1.000000e-09
GCST006585_2686	Blood protein levels	2.000000e-06

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004337	intelligence
EFO:0004340	body mass index
EFO:0006335	systolic blood pressure
EFO:0006527	smoking status measurement
EFO:0006336	diastolic blood pressure

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, decreases methylation	3
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression	3
Particulate Matter	increases abundance, increases expression, affects cotreatment, decreases expression	3
Benzo(a)pyrene	affects methylation, decreases expression, decreases methylation	2
Tobacco Smoke Pollution	affects expression, increases expression	2
Valproic Acid	increases expression, increases methylation	2
Cadmium Chloride	decreases expression, increases expression	2
aristolochic acid I	increases expression	1
methyleugenol	decreases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
beta-lapachone	decreases expression, increases expression	1
mono-(2-ethylhexyl)phthalate	decreases expression	1
cupric chloride	decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
corosolic acid	increases expression	1
monomethylarsonous acid	decreases expression	1
MT19c compound	decreases expression	1
Sunitinib	decreases expression	1
Acetaminophen	increases expression	1
Air Pollutants	increases abundance, increases expression	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1
Calcitriol	increases expression	1
Estradiol	decreases expression	1
Gasoline	affects cotreatment, increases abundance, increases expression	1
N-Nitrosopyrrolidine	decreases expression	1
Nicotine	increases expression	1
Polycyclic Aromatic Hydrocarbons	increases abundance, increases expression, affects cotreatment	1
Smoke	increases expression	1
Toluene	decreases expression	1
Tretinoin	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.